Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

San Diego Convention Center

Jun 23, 2019 2:30 PM - Jun 27, 2019 6:00 PM

111 W Harbor Drive, , San Diego, CA 92101 , USA

DIA 2019 Global Annual Meeting

Join thousands of your peers at the life sciences event of the year!

Neurodegenerative Diseases: Early-Stage Challenges and Optimal Models in Drug Development

Session Chair(s)

Dinah  Duarte, MSc

Dinah Duarte, MSc

Signal Management Lead

European Medicines Agency, Netherlands

Intense research on the multiple fronts advanced our understanding of neurodegenerative diseases. Many disease-specific animal models have been used to test emergent medicines in neurology. Genetics and mechanism of neuronal pathogenesis contributed greatly and has created a wealth of knowledge and became the bases for novel technologies and multiple therapeutic targets for these neurodegenerative diseases. There is however substantial difficulty in choosing/accessing an optimal model or choosing measurements which would be truly informative of the product’s efficacy in neurodegenerative rare diseases or more prevalent diseases like pediatric neurodegenerative diseases and Alzheimer’s. This session will discuss nonclinical models supporting efficacy in rare neurodegenerative conditions, looking also at the challenges in early development in pediatric neurodegenerative diseases and highlight successes and failures in the development of treatments for dyslipidemia that may be applicable to the treatment of neurodegenerative diseases like Alzheimer’s disease.

Learning Objective : Describe the importance and value of nonclinical in vivo models in rare neurodegenerative conditions and share highlights on the challenges in early development in pediatric neurodegenerative diseases; Identify optimal strategies for testing putative Alzheimer therapies; Recognize how to select and qualify biomarkers to identify patient and measure relevant drug activity; Define how to apply lessons from development of drugs to prevent Alzheimer Dementia.

Speaker(s)

Dinah  Duarte, MSc

Rare Neurodegenerative Diseases: Early-Stage Challenges and Optimal Animal Models in Orphan Drug Development

Dinah Duarte, MSc

European Medicines Agency, Netherlands

Signal Management Lead

Richard  Scheyer, MD

Alzheimers Disease Prophylaxis: Lessons from Lipid Therapeutics

Richard Scheyer, MD

Medpace, United States

Vice President, Medical

Scott  Demarest, MD

The Challenges in Early Development in pediatric Neurodegenerative Diseases

Scott Demarest, MD

University of Colorado School of Medicine; Children's Hospital Colorado, United States

Assistant Professor, Departments of Pediatrics and Neurology

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.